MEDINET Co., Ltd. (2370.T)
JPY 37.0
(0.0%)
JPY 37.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.49 Billion JPY | 4.32% |
| 2022 | 1.46 Billion JPY | 15.86% |
| 2021 | 1.26 Billion JPY | 3.58% |
| 2020 | 1.21 Billion JPY | -13.57% |
| 2019 | 1.4 Billion JPY | -53.53% |
| 2018 | 3.03 Billion JPY | 17.92% |
| 2017 | 2.57 Billion JPY | 1.14% |
| 2016 | 2.54 Billion JPY | 5.25% |
| 2015 | 2.41 Billion JPY | 8.16% |
| 2014 | 2.23 Billion JPY | 17.29% |
| 2013 | 1.9 Billion JPY | 2.14% |
| 2012 | 1.86 Billion JPY | -6.06% |
| 2011 | 1.98 Billion JPY | 7.86% |
| 2010 | 1.83 Billion JPY | 6.65% |
| 2009 | 1.72 Billion JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 364.45 Million JPY | -0.24% |
| 2024 Q2 | 365.34 Million JPY | -0.92% |
| 2024 Q1 | 368.75 Million JPY | -9.57% |
| 2023 Q4 | 407.78 Million JPY | 8.32% |
| 2023 FY | 1.52 Billion JPY | 4.32% |
| 2023 Q2 | 368.19 Million JPY | -0.96% |
| 2023 Q3 | 376.47 Million JPY | 2.25% |
| 2023 Q1 | 371.74 Million JPY | -2.91% |
| 2022 FY | 1.46 Billion JPY | 15.86% |
| 2022 Q4 | 382.89 Million JPY | 15.6% |
| 2022 Q2 | 367.33 Million JPY | -3.22% |
| 2022 Q1 | 379.56 Million JPY | 15.4% |
| 2022 Q3 | 331.23 Million JPY | -9.83% |
| 2021 Q3 | 336.8 Million JPY | 25.97% |
| 2021 Q1 | 327.97 Million JPY | 0.89% |
| 2021 Q2 | 267.36 Million JPY | -18.48% |
| 2021 Q4 | 328.91 Million JPY | -2.34% |
| 2021 FY | 1.26 Billion JPY | 3.58% |
| 2020 FY | 1.21 Billion JPY | -13.57% |
| 2020 Q4 | 325.08 Million JPY | 12.25% |
| 2020 Q1 | 314.77 Million JPY | 7.04% |
| 2020 Q2 | 288.03 Million JPY | -8.5% |
| 2020 Q3 | 289.6 Million JPY | 0.55% |
| 2019 Q1 | 379.75 Million JPY | -10.24% |
| 2019 Q3 | 371.49 Million JPY | 2.23% |
| 2019 Q4 | 294.05 Million JPY | -20.84% |
| 2019 FY | 1.4 Billion JPY | -53.53% |
| 2019 Q2 | 363.4 Million JPY | -4.3% |
| 2018 Q2 | 476.9 Million JPY | -70.91% |
| 2018 Q3 | 491.81 Million JPY | 3.13% |
| 2018 FY | 3.03 Billion JPY | 17.92% |
| 2018 Q1 | 1.63 Billion JPY | 211.57% |
| 2018 Q4 | 423.06 Million JPY | -13.98% |
| 2017 Q1 | 606.24 Million JPY | -23.27% |
| 2017 FY | 2.57 Billion JPY | 1.14% |
| 2017 Q2 | 826.44 Million JPY | 36.32% |
| 2017 Q4 | 526.19 Million JPY | -13.99% |
| 2017 Q3 | 611.77 Million JPY | -25.98% |
| 2016 Q4 | 790.06 Million JPY | 28.61% |
| 2016 Q1 | 556 Million JPY | -21.2% |
| 2016 Q2 | 581.42 Million JPY | 4.57% |
| 2016 Q3 | 614.29 Million JPY | 5.65% |
| 2016 FY | 2.54 Billion JPY | 5.25% |
| 2015 FY | 2.41 Billion JPY | 8.16% |
| 2015 Q2 | 535.17 Million JPY | -7.78% |
| 2015 Q4 | 705.54 Million JPY | 18.81% |
| 2015 Q3 | 593.83 Million JPY | 10.96% |
| 2015 Q1 | 580.33 Million JPY | 2.76% |
| 2014 Q2 | 557.11 Million JPY | 0.95% |
| 2014 FY | 2.23 Billion JPY | 17.29% |
| 2014 Q4 | 564.76 Million JPY | 1.05% |
| 2014 Q3 | 558.86 Million JPY | 0.31% |
| 2014 Q1 | 551.87 Million JPY | 12.53% |
| 2013 Q2 | 484.13 Million JPY | 15.89% |
| 2013 Q3 | 511.24 Million JPY | 5.6% |
| 2013 Q4 | 490.41 Million JPY | -4.07% |
| 2013 FY | 1.9 Billion JPY | 2.14% |
| 2013 Q1 | 417.76 Million JPY | -4.17% |
| 2012 Q3 | 493.77 Million JPY | 5.8% |
| 2012 Q1 | 467.25 Million JPY | -11.17% |
| 2012 FY | 1.86 Billion JPY | -6.06% |
| 2012 Q2 | 466.71 Million JPY | -0.12% |
| 2012 Q4 | 435.92 Million JPY | -11.72% |
| 2011 FY | 1.98 Billion JPY | 7.86% |
| 2011 Q3 | 556.82 Million JPY | 20.2% |
| 2011 Q2 | 463.25 Million JPY | 5.83% |
| 2011 Q4 | 526 Million JPY | -5.53% |
| 2011 Q1 | 437.73 Million JPY | -10.04% |
| 2010 Q3 | 500.14 Million JPY | 12.53% |
| 2010 Q1 | 408.09 Million JPY | -17.73% |
| 2010 FY | 1.83 Billion JPY | 6.65% |
| 2010 Q4 | 486.59 Million JPY | -2.71% |
| 2010 Q2 | 444.45 Million JPY | 8.91% |
| 2009 Q4 | 496.04 Million JPY | 19.73% |
| 2009 Q2 | 414.78 Million JPY | 3.83% |
| 2009 FY | 1.72 Billion JPY | 0.0% |
| 2009 Q1 | 399.5 Million JPY | 0.0% |
| 2009 Q3 | 414.29 Million JPY | -0.12% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | -16.091% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -158.516% |
| GNI Group Ltd. | 9.32 Billion JPY | 84.004% |
| Linical Co., Ltd. | 2.7 Billion JPY | 44.878% |
| Trans Genic Inc. | 2.15 Billion JPY | 30.959% |
| Soiken Holdings Inc. | 3.07 Billion JPY | 51.445% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | 19.7% |
| AnGes, Inc. | 8.9 Billion JPY | 83.25% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | -58.116% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 92.229% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -261.064% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | -52.881% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | 41.923% |
| CanBas Co., Ltd. | 278 Million JPY | -436.388% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | -30.628% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | 17.976% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | 7.021% |
| Kidswell Bio Corporation | 2.37 Billion JPY | 37.19% |
| PeptiDream Inc. | 9.68 Billion JPY | 84.607% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | 23.943% |
| Ribomic Inc. | 1.1 Billion JPY | -34.862% |
| SanBio Company Limited | 4.53 Billion JPY | 67.148% |
| Healios K.K. | 3.48 Billion JPY | 57.237% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | -29.134% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | -11.742% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | -6.249% |
| StemRIM | 2.07 Billion JPY | 28.172% |
| CellSource Co., Ltd. | 1.96 Billion JPY | 24.056% |
| FunPep Company Limited | 313.82 Million JPY | -375.162% |
| Kringle Pharma, Inc. | 958.01 Million JPY | -55.651% |
| Stella Pharma Corporation | 963.98 Million JPY | -54.687% |
| TMS Co., Ltd. | 943.25 Million JPY | -58.087% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | -36.81% |
| Cuorips Inc. | 598.11 Million JPY | -149.308% |
| K Pharma,Inc. | 543.94 Million JPY | -174.139% |
| Takara Bio Inc. | 23.9 Billion JPY | 93.762% |
| ReproCELL Incorporated | 1.51 Billion JPY | 1.51% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | -25.944% |
| StemCell Institute Inc. | 1.16 Billion JPY | -28.313% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | 2.044% |
| CellSeed Inc. | 804.93 Million JPY | -85.253% |